NIH Notice: Expiration of PAR-25-326 Ultra-Rare Gene Therapy Network Access

NIH Guide Weekly Index

Published March 12th, 2026

Detected March 13th, 2026

Summary

The National Institute of Neurological Disorders and Stroke (NINDS) issued a notice announcing the immediate expiration of Funding Opportunity Announcement PAR-25-326 for Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access. No further applications will be accepted under this announcement.

View original document View source feed page

What changed

The National Institute of Neurological Disorders and Stroke (NINDS) has issued a notice to the extramural research community announcing the immediate expiration of the Funding Opportunity Announcement (FOA) PAR-25-326, which pertained to Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed). This means no new applications will be accepted under this specific FOA.

Researchers interested in the URGenT program are directed to apply to a related, but distinct, FOA, PAR-25-327, which focuses on Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional). This change primarily affects entities that were planning to submit applications under PAR-25-326, requiring them to pivot to the alternative funding opportunity if their research aligns with its scope.

What to do next

Review PAR-25-327 for potential application to URGenT program research
Discontinue submission of applications under PAR-25-326

Source document (simplified)

Notice of Change: Early Expiration of PAR-25-326 Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed) Notice Number: NOT-NS-26-032

Key Dates

Release Date: March 12, 2026

Related Announcements

December 18, 2024 - Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed). See NOFO PAR-25-326.

Issued by

National Institute of Neurological Disorders and
Stroke (NINDS)

Purpose

The purpose of this notice is to inform the extramural community that, effective immediately, the following NOFO is expired:

PAR-25-326: Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed). No further applications will be accepted for PAR-25-326.

Applicants interested in applying to the Ultra-rare Gene-based Therapy (URGenT) program are encouraged to continue applying to the following NOFO:

PAR-25-327: Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)